Clinical Trial: Efficacy and Safety of Neoadjuvant Serplulimab Combined with Platinum-Based Doublet Chemotherapy and SBRT in Patients with Resectable or Potentially Resectable Stage IB–IIIB Small Cell Lung Cancer: A Phase 2 Study (China)

China, Aug. 27 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Neoadjuvant Serplulimab Combined with Platinum-Based Doublet Chemotherapy and SBRT in Patients with Resectable or Potentially Resectable Stage IB–IIIB Small Cell Lung Cancer: A Phase 2 Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130978

Registration Time: 2026/08/27

Type: Interventional study

Primary Sponsor: Shanghai Pulmonary Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=332702

Published by HT Digital Content Services with permission from Health Daily Digest....